These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30387762)

  • 21. Identification of Aptamers That Bind to Sickle Hemoglobin and Inhibit Its Polymerization.
    Purvis SH; Keefer JR; Fortenberry YM; Barron-Casella EA; Casella JF
    Nucleic Acid Ther; 2017 Dec; 27(6):354-364. PubMed ID: 29039727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.
    Omar AM; Mahran MA; Ghatge MS; Chowdhury N; Bamane FH; El-Araby ME; Abdulmalik O; Safo MK
    Org Biomol Chem; 2015 Jun; 13(22):6353-70. PubMed ID: 25974708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling.
    Nakagawa A; Lui FE; Wassaf D; Yefidoff-Freedman R; Casalena D; Palmer MA; Meadows J; Mozzarelli A; Ronda L; Abdulmalik O; Bloch KD; Safo MK; Zapol WM
    ACS Chem Biol; 2014 Oct; 9(10):2318-25. PubMed ID: 25061917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Membrane modifiers in sickle cell disease.
    Benjamin LJ
    Ann N Y Acad Sci; 1989; 565():247-61. PubMed ID: 2672964
    [No Abstract]   [Full Text] [Related]  

  • 25. A "Split" Hemoglobin S Peak.
    Colby JM; Shajani-Yi Z
    Clin Chem; 2020 Sep; 66(9):1250-1251. PubMed ID: 32870996
    [No Abstract]   [Full Text] [Related]  

  • 26. Pathogenesis and treatment of sickle cell disease.
    Bunn HF
    N Engl J Med; 1997 Sep; 337(11):762-9. PubMed ID: 9287233
    [No Abstract]   [Full Text] [Related]  

  • 27. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes.
    Beddell CR; Goodford PJ; Kneen G; White RD; Wilkinson S; Wootton R
    Br J Pharmacol; 1984 Jun; 82(2):397-407. PubMed ID: 6733364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seeking a way to alleviate sickle cell disease.
    Mitka M
    JAMA; 2002 Oct 23-30; 288(16):1970. PubMed ID: 12387636
    [No Abstract]   [Full Text] [Related]  

  • 29. Pathophysiologically based drug treatment of sickle cell disease.
    Steinberg MH
    Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-throughput assessment of hemoglobin polymer in single red blood cells from sickle cell patients under controlled oxygen tension.
    Di Caprio G; Schonbrun E; Gonçalves BP; Valdez JM; Wood DK; Higgins JM
    Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25236-25242. PubMed ID: 31767751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding antisickling agents and the sickling process.
    Godwin M; Baysinger M
    Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
    [No Abstract]   [Full Text] [Related]  

  • 32. Influence of sickle hemoglobin polymerization and membrane properties on deformability of sickle erythrocytes in the microcirculation.
    Dong C; Chadwick RS; Schechter AN
    Biophys J; 1992 Sep; 63(3):774-83. PubMed ID: 1420913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of phenylalanine derivatives on the solubility of deoxyhemoglobin S. A model class of gelation inhibitors.
    Noguchi CT; Ackerman S; DiMaio J; Schiller PW; Schechter AN
    Mol Pharmacol; 1983 Jan; 23(1):100-3. PubMed ID: 6865893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
    Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
    [No Abstract]   [Full Text] [Related]  

  • 35. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease.
    Henry ER; Cellmer T; Dunkelberger EB; Metaferia B; Hofrichter J; Li Q; Ostrowski D; Ghirlando R; Louis JM; Moutereau S; Galactéros F; Thein SL; Bartolucci P; Eaton WA
    Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15018-15027. PubMed ID: 32527859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Solubility measurement of the sickle polymer.
    Fabry ME; Acharya SA; Suzuka SM; Nagel RL
    Methods Mol Med; 2003; 82():271-87. PubMed ID: 12669649
    [No Abstract]   [Full Text] [Related]  

  • 38. Sickle hemoglobin aggregation: a new class of inhibitors.
    Votano JR; Gorecki M; Rich A
    Science; 1977 Jun; 196(4295):1216-9. PubMed ID: 870976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiological and x-ray studies of potential antisickling agents.
    Abraham DJ; Perutz MF; Phillips SE
    Proc Natl Acad Sci U S A; 1983 Jan; 80(2):324-8. PubMed ID: 6572894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The reaction of deoxy-sickle cell hemoglobin with hydroxyurea.
    Kim-Shapiro DB; King SB; Shields H; Kolibash CP; Gravatt WL; Ballas SK
    Biochim Biophys Acta; 1999 Aug; 1428(2-3):381-7. PubMed ID: 10434057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.